Clinical trial NCT00391131: Subcutaneous Ig NextGen 16% in PID Patients
Official title: A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Immunodeficiency (PID)
Keywords: PID
SCIG
Ig
Quality of Life
Serious Bacterial Infections
Lead sponsor: CSL Limited
Sponsor class: INDUSTRY
First posted: 2006-10-23
Enrollment: 35
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to assess the safety, tolerability, efficacy and pharmacokinetics of Ig NextGen 16% in people with antibody deficiency currently being treated with IntragamP. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation manufactured using predominately chromatographic techniques. Eligible patients will switch from monthly intravenous IntragamP therapy to weekly subcutaneous Ig NextGen 16% treatment. Initial hospital training will be required for subcutaneous administration and then the patient will perform the infusion in their own home, returning once a month for a supervised infusion. Patients will be monitored on the study for up to 10 months to assess blood IgG levels and rate of serious bacterial infections.


Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria:

  * Males or females 3 years of age or greater and at least 13 kg at enrolment.
  * PID patients receiving Ig replacement therapy, with a diagnosis of X-linked agammaglobulinemia (XLA) or Common Variable immunodeficiency (CVID) with severe hypogammaglobulinemia.
  * Patients who have received a consistent dose of Intragam®P at 3-, 4-, 5- or 6-weekly intervals, within the range of 0.2 - 0.6 g/kg body weight, for at least six months prior to the Screening visit.
  * Patients must have maintained IgG trough serum level of ≥ 5 g/L during the six months prior to Visit 0, with at least two trough levels to have been documented during this period.
  * Patients and/or their legally acceptable representative/guardian must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements

Exclusion Criteria:

* • Patients newly diagnosed with PID within six months of the Screening visit.

  * Patients with known or suspected severe hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy or other blood products
  * Patients with known selective IgA deficiency or antibodies to IgA
  * Patients receiving immunosuppressive treatment other than topical and/or inhaled steroids and low dose oral steroids.
  * Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Females who are of child bearing potential must have a negative pregnancy test at screening.
  * Patients with protein-losing enteropathies, and kidney diseases with substantial proteinuria
  * Patients with malignancies of lymphoid cells such as chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma.
  * Patients who have within 30 days priors to the study screening visit, participated in a clinical study or used an investigational compound (eg: a new chemical entity not registered for clinical use).
  * Patients with any of the following abnormal lab results:

    * Serum creatinine \>1.5 x Upper limit of Normal (ULN).
    * Serum ALT \& AST \> 2.5 x ULN.
    * Albumin \< 25 g/L
  * Patients who are suffering from an acute or chronic medical condition, other than PID, which may, in the opinion of the Investigator, affect the conduct of the trial.
  * Patients who are not willing or are unable to comply with protocol.

Primary outcomes:
measure: Efficacy
timeFrame: Continually from Visits 7 to 12 & monthly IgG troughs
Secondary outcomes:
measure: Safety, Tolerability, Quality of Life, Pharmacokinetics
timeFrame: Visits 0, 6, 9, and12
Other outcomes:
Locations:
city: Garran
country: Australia
facility: The Canberra Hospital
state: Australian Capital Territory
city: New Lambton Heights
country: Australia
facility: John Hunter Hospital
state: New South Wales
city: Randwick
country: Australia
facility: Sydney Children's Hospital
state: New South Wales
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital
state: South Australia
city: North Adelaide
country: Australia
facility: Women's & Children's Hospital
state: South Australia
city: Frankston
country: Australia
facility: Frankston Hospital
state: Victoria
city: Melbourne
country: Australia
facility: Royal Children's Hospital
state: Victoria
city: Perth
country: Australia
facility: Princess Margaret Hospital for Children
state: Western Australia
city: Auckland
country: New Zealand
facility: Auckland Hospital
city: Auckland
country: New Zealand
facility: Starship Children's Hospital
city: Christchurch
country: New Zealand
facility: Christchurch Hospital
city: Wellington
country: New Zealand
facility: Wellington Hospital
Study officials:
affiliation: Auckland City Hospital
name: Marianne Empson, Dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Empson MB, Tang ML, Pearce LK, Rozen L, Gold MS, Katelaris CH, Langton D, Smart J, Smith WB, Steele RH, Ziegler JB, Maher D. Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency. J Clin Immunol. 2012 Oct;32(5):897-906. doi: 10.1007/s10875-011-9641-4. Epub 2012 Apr 13.